Abstract: Methods and compositions are provided for diagnosing lung cancer in a mammalian subject by use of three or more selected genes, e.g., a gene expression profile, from the peripheral blood mononuclear cells (PBMC) of the subject which is characteristic of disease, a stage of the disease, or enables prognosis of recurrence of disease. The gene expression profile includes three or more genes of Table I, Table II, Table III, Table IV, Table V, Table VI or Table VII herein. Detection of changes in expression in the selected genes forming the gene expression profile from that of a reference gene expression profile are correlated with non-small cell lung cancer (NSCLC). One composition for use in such diagnosis includes three or more PCR primer-probe sets, wherein each primer-probe set amplifies a different polynucleotide sequence from the gene expression profile.

Abstract: The present invention provides multiple antigenic agents compositions and the use thereof to prevent or treat viral infections.

Abstract: An isolated nucleic acid sequence of BRAF35 and polypeptides encoded thereby are provided, as well as a multiprotein complex, and an antibody capable of binding selectively to the BRAF35 protein. Related agents and compositions which modulate interaction between BRCA2 and BRAF35 and methods of their use for screening for the BRCA2 protein, suppressing tumors and identifying DNA damage in cells indicative of a risk for developing cancer are also provided.

Abstract: Use as an anti-cancer agent of a mutant herpes simplex virus wherein the mutant virus comprises a modification in the ?34.5 gene in the long repeat region (RL) such that the ?34.5 gene is a non-functional, manufacture of medicaments and methods of testing cancer in mammals employing HSV mutant.

Abstract: The present invention provides peptides and peptidomimetics corresponding to part or to the entirety of the region encompassed by residues 360-386 of human p53, said peptides and peptidomimetics characterized by the ability to activate DNA binding of wild-type p53 and of select tumor-derived p53 mutants. Pharmaceutical compositions of the compounds of the invention and methods of using these compositions therapeutically are also provided.

Abstract: A method of developing a gene expression profile indicative of the presence or stage of a selected a disease, disorder or genetic pathology in a mammalian subject employs penalized discriminant analysis with recursive feature elimination. A method of diagnosing a cancer in a mammalian subject includes the steps of examining a sample containing the subject's immune cells and detecting a variance in the expression of a statistically significant number of genes, e.g., at least 10 non-tumor genes from those same genes in a characteristic disease or healthy gene expression profile. A significant variance in expression of these genes when compared to a gene expression profile, preferably an average gene expression profile of a normal control, or significant similarities to an average gene profile of subjects with cancer, correlates with a specific type of cancer and/or location of tumor.

Abstract: A three-dimensional reconstruct model containing solid layers of collagen and fibroblasts closely mimic the condition of patients in vivo, preserving in vivo phenotypic and functional characteristics of the cells. Reconstructs can be used to detect cellular migration, including active migration of cytotoxic T lymphocytes towards tumor cells, which can be measured by detecting tumor cell lysis. Reconstructs also can be used to identify factors that influence migration of cells, including chemokines that influence migration of cytotoxic T lymphocytes, as well as to identify tumor antigens.

Abstract: The present invention provides multiple antigenic agents compositions and the use thereof to prevent or treat viral infections.

Abstract: The present invention is a method distinguishing between head and neck squamous cell carcinoma and lung squamous cell carcinoma. In particular, a 10-gene classifier has been identified which can be used to distinguish between primary squamous cell carcinoma of the lung and metastatic head and neck squamous cell carcinoma. These genes include CXCL13, COL6A2, SFTPB, KRT14, TSPYL5, TMP3, KLK10, MMP1, GAS1, and MYH2. A panel of one or more of these genes, or proteins encoded thereby, can be used for early diagnosis and selection of an appropriate therapeutic treatment.

Abstract: Mice in which enhance wound healing occurs can be used to identify genes and gene products which are involved in enhanced wound healing in mammals, including humans. Methods and compositions for treating wounds, including central and peripheral nerve wounds, are also provided.

Abstract: The invention provides a method of delivering a selected DNA sequence to the central nervous system of a mammal by administering to said mammal a neurotropic virus, said virus containing a selected DNA sequence under the control of a promoter which permits expression of the DNA during the latent infectious state of the virus.

Abstract: The present invention provides multiple antigenic agents compositions and the use thereof to prevent or treat viral infections. The multiple antigenic agents of the invention contain at least one of a B cell determinant, a T cell determinant, or a targeting molecule attached to a core peptide composed of Lys-Gly repeats.

Abstract: The present invention provides peptides and peptidomimetics corresponding to part or to the entirety of the region encompassed by residues 360-386 of human p53, said peptides and peptidomimetics characterized by the ability to activate DNA binding of wild-type p53 and of select tumor-derived p53 mutants. Pharmaceutical compositions of the compounds of the invention and methods of using these compositions therapeutically are also provided.

Abstract: A method for detecting DNA damage in a tissue sample involves contacting an immobilized biological sample with a labeled ligand which binds to human 53Bp1, and examining the immobilized sample for the presence of a label generated-detectable signal concentrated in foci in said sample. The presence of concentrated foci is indicative of DNA damage and the presence of diffuse signal is indicative of a normal sample. Diagnostic reagents contain a ligand that binds to human 53Bp1 associated with a detectable label. Diagnostic kits for detecting DNA damage in a biological sample contain such diagnostic reagents and signal detection components. Compositions that inhibit or antagonize the biological activity of 53Bp1 are identified by suitable assays, and are employed in methods of retarding the growth of a cancer cell.

Abstract: An organotypic culture comprises an artificial stroma overlayed with epithelial cells isolated from a human colon or intestine. The stroma comprises a mixture of collagen and human fibroblasts isolated from a human colon or intestine. The culture contains a factor that binds the IGF-1 receptor, a factor that binds the EGF receptor, and a factor that binds the LIF receptor. These factors may be added exogenously to the culture via medium or may be expressed by various recombinantly engineered cell types in the culture. The organotypic culture can result in growth that is in situ-like or emphasizes other physiological or morphological states, depending on the balance of factors in the growth media. The organotypic culture may be used in methods for screening of therapeutic, carcinogenic, or growth enhancement factors, or for treating intestinal injuries by applying to the site of an injury the intact culture or the components thereof.

Abstract: The present invention provides peptides and peptidomimetics corresponding to part or to the entirety of the region encompassed by residues 360–386 of human p53, said peptides and peptidomimetics characterized by the ability to activate DNA binding of wild-type p53 and of select tumor-derived p53 mutants. Pharmaceutical compositions of the compounds of the invention and methods of using these compositions therapeutically are also provided.

Abstract: An isolated nucleic acid sequence of a mitotic checkpoint gene, chfr, encodes a Chfr protein having a Forkhead-associated domain and a Ring Finger. This protein is required for regulation of the transition of cells from prophase to metaphase during mitosis. The chfr nucleic acid and Chfr polypeptide are useful in diagnosing tumorigenic cells and in screening for drugs which can inhibit the activity of Chfr in a cancer cell, thereby rendering the cell more sensitive to additional anti-tumor therapies.

Abstract: The present invention provides Bin2 sequences and proteins encoded thereby. Also provided are compositions and methods utilizing these sequences and proteins in the diagnosis and treatment of blood disorders, including hepatocarcinoma. Further provided are oligonucleotides derived from sequences encoding Bin2, as well as compositions and methods utilizing same for diagnostic and therapeutic purposes.

Abstract: A method of developing a gene expression profile indicative of the presence or stage of a selected a disease, disorder or genetic pathology in a mammalian subject employs penalized discriminant analysis with recursive feature elimination. A method of diagnosing a cancer in a mammalian subject includes the steps of examining a sample containing the subject's immune cells and detecting a variance in the expression of a statistically significant number of genes, e.g., at least 10 non-tumor genes from those same genes in a characteristic disease or healthy gene expression profile. A significant variance in expression of these genes when compared to a gene expression profile, preferably an average gene expression profile of a normal control, or significant similarities to an average gene profile of subjects with cancer, correlates with a specific type of cancer and/or location of tumor.

Abstract: A method for identifying a compound that has a biocidal effect against a selected organism involves screening from among known or unknown peptide or non-peptide molecules, a test molecule that binds selectively to a target sequence of a multi-helical lid of a heat shock protein of the organism. The binding of the test compound inhibits the protein folding activity of the protein. A specific embodiment of such a method is useful for identifying or designing a pharmaceutical or veterinary biocidal or antibiotic compound, preferably a pathogen and/or strain-specific compound. For this purpose, the compound does not bind to a heat shock protein that is homologous to the mammalian subject to be treated with the compound. Screening methods can encompass direct binding or competitive assays. Molecules or compounds identified by these methods are employed as biocides for pharmaceutical, veterinary, pesticide, insecticide and rodenticide uses, among others.